vadastuximab talirine + decitabine

Vadastuximab talirine + decitabine is a combination therapy studied in frontline acute myeloid leukemia (AML) for patients ineligible for intensive chemotherapy. Vadastuximab talirine is a CD33-targeted antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting CD33, conjugated via a protease-cleavable dipeptide linker (maleimidocaproyl-valine-alanine) to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Upon binding CD33 on myeloid leukemia cells, the conjugate is internalized, releases the DNA-crosslinking PBD in lysosomes, and induces DNA crosslinks, cell cycle arrest, and apoptosis in CD33-positive cells. Decitabine is a small-molecule hypomethylating agent and cytidine analogue, incorporated into DNA where it inhibits DNA methyltransferases, leading to global DNA hypomethylation, reactivation of tumor suppressor genes, and impaired proliferation of malignant cells. The combination is designed to potentiate cytotoxicity by upregulating CD33 expression and DNA susceptibility to the PBD ADC. The primary use investigated is for AML, particularly in elderly patients or those unfit for intensive regimens[1][2][3][5].

Brand names

Inqovi 5 Tablet PackInqovi5 Tablet PackInqovi-5 Tablet Pack

Other names

vadastuximab talirinedecitabine5-aza-2'-deoxycytidine